title: Liposomal doxorubicin: Effective treatment for pediatric desmoid fibromatosis.
abstract: Efficacy of liposomal doxorubicin (LD) in treating desmoid fibromatosis (DF) in children has not been well evaluated. This retrospective case series examines five children with progressive DF, treated with LD. We report progression-free intervals (PFIs) and radiographic as well as clinical responses for each medication received. LD was well tolerated, with an average 4.5% reduction in tumor size and median PFI of 29 months. Treatment with LD conferred the longest PFI of all medical therapies pursued. Thus, LD is an important treatment option for DF in pediatrics.
authors.affiliation: Department of Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
authors.forename: Prasanna
authors.initials: P
authors.lastname: Ananth
authors.affiliation: Department of Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
authors.forename: Annette
authors.initials: A
authors.lastname: Werger
authors.affiliation: Department of Radiology, Boston Children's Hospital, Boston, Massachusetts.
authors.forename: Stephan
authors.initials: S
authors.lastname: Voss
authors.affiliation: Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee.
authors.forename: Carlos
authors.initials: C
authors.lastname: Rodriguez-Galindo
authors.affiliation: Department of Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
authors.forename: Katherine A
authors.initials: KA
authors.lastname: Janeway
mesh_terms: D000293:Adolescent; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D018222:Desmoid Tumors / Q000188:drug therapy*; D006801:Humans; D008297:Male; D011092:Polyethylene Glycols / Q000627:therapeutic use; D012189:Retrospective Studies
chemical_list: D000903:Antibiotics, Antineoplastic; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin
keywords: RECIST; desmoid fibromatosis; liposomal doxorubicin; pediatric; progression-free interval